Candriam S.C.A. Nurix Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 1,061,959 shares of NRIX stock, worth $22.1 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
1,061,959
Previous 1,164,246
8.79%
Holding current value
$22.1 Million
Previous $24.3 Million
1.88%
% of portfolio
0.14%
Previous 0.15%
Shares
15 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$142 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$89.1 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$83.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$80.8 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$80.5 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $981M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...